Literature DB >> 3227056

Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders.

W A Nolen1, G S Jansen, M Broekman.   

Abstract

Twenty-four patients suffering from affective disorders, who were being regularly treated with carbamazepine, were studied to determine the course of plasma levels of carbamazepine before (trough levels) and two and four hours after morning intake (peak levels). A large interindividual variation was found between highest peak level and trough level. Despite the lack of systematic studies it is concluded that measuring plasma levels to determine the therapeutic range of carbamazepine should use trough levels, which should provisionally be aimed at between six and eight mg/l. In order to avoid adverse effects, peak levels should not exceed 12 (or even 10) mg/l.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3227056     DOI: 10.1055/s-2007-1016965

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

1.  A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results.

Authors:  A J Loonen; P J Toll; J R Nijdam
Journal:  Pharm Weekbl Sci       Date:  1989-02-24

2.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.